HKSE - Delayed Quote HKD

Charmacy Pharmaceutical Co., Ltd. (2289.HK)

7.750
0.000
(0.00%)
As of May 2 at 1:56:38 PM GMT+8. Market Open.
Loading Chart for 2289.HK
  • Previous Close 7.750
  • Open 7.750
  • Bid --
  • Ask 7.750 x --
  • Day's Range 7.750 - 7.750
  • 52 Week Range 6.810 - 14.400
  • Volume 13,500
  • Avg. Volume 767
  • Market Cap (intraday) 837M
  • Beta (5Y Monthly) -0.71
  • PE Ratio (TTM) 14.62
  • EPS (TTM) 0.530
  • Earnings Date Mar 28, 2025
  • Forward Dividend & Yield 0.48 (6.18%)
  • Ex-Dividend Date May 26, 2025
  • 1y Target Est --

Charmacy Pharmaceutical Co., Ltd. engages in the pharmaceutical distribution business in the People's Republic of China. The company distributes western medicines, Chinese patent medicines, healthcare products, and related pharmaceutical products consulting services to downstream distributors and retail terminals. It also operates Charmacy e-Medicine, a B2B e-commerce platform to place orders online, make inquires and payments, etc. The company was formerly known as Chuangmei Pharmaceutical Co., Ltd. and changed its name to Charmacy Pharmaceutical Co., Ltd. in July 2016. Charmacy Pharmaceutical Co., Ltd. was incorporated in 1984 and is based in Shantou, the People's Republic of China.

www.chmyy.com

847

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 2289.HK

View More

Performance Overview: 2289.HK

Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2289.HK
20.92%
HANG SENG INDEX (^HSI)
13.54%

1-Year Return

2289.HK
42.90%
HANG SENG INDEX (^HSI)
24.36%

3-Year Return

2289.HK
30.03%
HANG SENG INDEX (^HSI)
13.87%

5-Year Return

2289.HK
27.64%
HANG SENG INDEX (^HSI)
6.00%

Compare To: 2289.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2289.HK

View More

Valuation Measures

Annual
As of 5/8/2025
  • Market Cap

    837.00M

  • Enterprise Value

    2.05B

  • Trailing P/E

    14.63

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.18

  • Price/Book (mrq)

    1.26

  • Enterprise Value/Revenue

    0.43

  • Enterprise Value/EBITDA

    11.46

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.20%

  • Return on Assets (ttm)

    2.52%

  • Return on Equity (ttm)

    8.76%

  • Revenue (ttm)

    4.44B

  • Net Income Avi to Common (ttm)

    53.28M

  • Diluted EPS (ttm)

    0.530

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    573.86M

  • Total Debt/Equity (mrq)

    227.81%

  • Levered Free Cash Flow (ttm)

    -69.75M

Research Analysis: 2289.HK

View More

Company Insights: 2289.HK

Research Reports: 2289.HK

View More

People Also Watch